Literature DB >> 17889534

Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.

Scott B Hoyt1, Clare London, Hyun Ok, Edward Gonzalez, Joseph L Duffy, Catherine Abbadie, Brian Dean, John P Felix, Maria L Garcia, Nina Jochnowitz, Bindhu V Karanam, Xiaohua Li, Kathryn A Lyons, Erin McGowan, D Euan Macintyre, William J Martin, Birgit T Priest, McHardy M Smith, Richard Tschirret-Guth, Vivien A Warren, Brande S Williams, Gregory J Kaczorowski, William H Parsons.   

Abstract

A series of benzazepinones were synthesized and evaluated as hNa(v)1.7 sodium channel blockers. Several compounds from this series displayed good oral bioavailability and exposure and were efficacious in a rat model of neuropathic pain.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17889534     DOI： 10.1016/j.bmcl.2007.09.032

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  16 in total

Review 1.  Na(+) channel blockers for the treatment of pain: context is everything, almost.

Authors:  Michael S Gold
Journal:  Exp Neurol       Date:  2007-12-08       Impact factor: 5.330

Review 2.  AMPK: An emerging target for modification of injury-induced pain plasticity.

Authors:  Theodore J Price; Gregory Dussor
Journal:  Neurosci Lett       Date:  2013-07-03       Impact factor: 3.046

Review 3.  [Neuropathic pain associated with Nav1.7 mutations: clinical picture and treatment].

Authors:  K Doppler; C Sommer
Journal:  Nervenarzt       Date:  2013-12       Impact factor: 1.214

Review 4.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 5.  The role of sodium channels in chronic pain.

Authors:  Simon R Levinson; Songjiang Luo; Michael A Henry
Journal:  Muscle Nerve       Date:  2012-08       Impact factor: 3.217

6.  GpTx-1 and [Ala5 , Phe6 , Leu26 , Arg28 ]GpTx-1, two peptide NaV 1.7 inhibitors: analgesic and tolerance properties at the spinal level.

Authors:  Chao Chen; Biao Xu; Xuerui Shi; Mengna Zhang; Qinqin Zhang; Ting Zhang; Weidong Zhao; Run Zhang; Zilong Wang; Ning Li; Quan Fang
Journal:  Br J Pharmacol       Date:  2018-09-09       Impact factor: 8.739

Review 7.  Neuropathic pain: a maladaptive response of the nervous system to damage.

Authors:  Michael Costigan; Joachim Scholz; Clifford J Woolf
Journal:  Annu Rev Neurosci       Date:  2009       Impact factor: 12.449

8.  Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain.

Authors:  Ohannes K Melemedjian; Marina N Asiedu; Dipti V Tillu; Raul Sanoja; Jin Yan; Arianna Lark; Arkady Khoutorsky; Jessica Johnson; Katherine A Peebles; Talya Lepow; Nahum Sonenberg; Gregory Dussor; Theodore J Price
Journal:  Mol Pain       Date:  2011-09-21       Impact factor: 3.395

9.  Electroacupuncture Reduces Carrageenan- and CFA-Induced Inflammatory Pain Accompanied by Changing the Expression of Nav1.7 and Nav1.8, rather than Nav1.9, in Mice Dorsal Root Ganglia.

Authors:  Chun-Ping Huang; Hsiang-Ni Chen; Hong-Lin Su; Ching-Liang Hsieh; Wei-Hsin Chen; Zhen-Rung Lai; Yi-Wen Lin
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-19       Impact factor: 2.629

Review 10.  Genes and epigenetic processes as prospective pain targets.

Authors:  Megan Crow; Franziska Denk; Stephen B McMahon
Journal:  Genome Med       Date:  2013-02-15       Impact factor: 11.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.